Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.39 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.39 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.39 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.39 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.39 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.39 |
| ▸ | MMP8 | P22894 | 2/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1081939 | 0.78 | HPGD (0.47) | CA2 | |
| SCHEMBL1081936 | 0.76 | PSEN1 (0.39) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6464770 | 0.73 | CA2 (0.49) | CA2SIGMAR1HTR1AADRA2AADRA2B | |
| SCHEMBL6591026 | 0.73 | CA2 (0.56) | CA2SIGMAR1HTR1AADRA2AADRA2B | |
| SCHEMBL4672085 | 0.73 | CA2 (0.49) | CA2SIGMAR1HTR1AADRA2AADRA2B | |
| SCHEMBL3641960 | 0.73 | CYP1A2 (0.51) | CA2SIGMAR1HTR1AADRA2AADRA2B | |
| SCHEMBL12064816 | 0.71 | CYP1A2 (0.54) | CA2SIGMAR1HTR1AADRA2AADRA2B | |
| SCHEMBL1365698 | 0.71 | CA2 (0.47) | CA2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL8510380 | 0.71 | CA2 (0.50) | CA2SIGMAR1HTR1AADRA2AADRA2B | |
| Acetic Acid SCHEMBL27984668 | 0.70 | CA2 (0.44) | CA2SIGMAR1HTR1AADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2027104-B1 | ARYLSULFONYLCHROMANS AS 5-HT6 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-02-23 | — | — | EP | disclosed |
| US-7754759-B2 | Arylsulfonyl chromans as 5-HT6 inhibitors | ROCHE PALO ALTO LLC (US) | 2010-07-13 | — | — | US | disclosed |
| US-7754759-B2 | Arylsulfonyl chromans as 5-HT6 inhibitors | ROCHE PALO ALTO LLC (US) | 2010-07-13 | — | — | US | disclosed |
| US-7528250-B2 | Chroman derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2009-05-05 | — | — | US | disclosed |
| EP-2027104-A1 | ARYLSULFONYLCHROMANS AS 5-HT6 INHIBITORS INDOLYLMALEIMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-02-25 | — | — | EP | disclosed |
| CN-101300246-A | Arylsulfonylchromans as 5-HT6 inhibitors indolylmaleimide derivatives as protein kinase inhibitors | HOFFMANN LA ROCHE (CH) | 2008-11-05 | — | — | CN | disclosed |
| CN-101300246-A | Arylsulfonylchromans as 5-HT6 inhibitors indolylmaleimide derivatives as protein kinase inhibitors | HOFFMANN LA ROCHE (CH) | 2008-11-05 | — | — | CN | disclosed |
| EP-1831203-A1 | CHROMAN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CNS DISORDERS | F. Hoffmann-Roche AG (CH) | 2007-09-12 | — | — | EP | disclosed |
| WO-2007051735-A1 | ARYLSULFONYLCHROMANS AS 5-HT6 INHIBITORS INDOLYLMALEIMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-10 | — | — | WO | disclosed |
| US-20070099908-A1 | Arylsulfonyl chromans as 5-HT6 inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-03 | — | — | US | disclosed |
| US-20070099908-A1 | Arylsulfonyl chromans as 5-HT6 inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-03 | — | — | US | disclosed |
| US-20060148820-A1 | Chroman derivatives and uses thereof | ROCHE PALO ALTO LLC | 2006-07-06 | — | — | US | disclosed |
| WO-2006066756-A1 | CHROMAN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148820-A1 | Chroman derivatives and uses thereof | RB1, RECQL, CCNY | CA2 2409/4885PSEN1 2988/4885PSEN2 3495/4885 |
| US-20070099908-A1 | Arylsulfonyl chromans as 5-HT6 inhibitors | HTR6, HTR1F, HTR1A | CA2 4390/4885PSEN1 2038/4885PSEN2 2294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.